Episodic vs. Chronic Migraine — Why the Distinction Drives Everything
The episodic/chronic distinction determines which treatments qualify, which ICD-10 codes apply, and which denial pathways will be used against you.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
The clinical and PA significance of the threshold. Episodic migraine is defined as fewer than 15 headache days per month; chronic migraine is 15 or more headache days per month for at least three months, with at least eight of those days meeting migraine criteria. The distinction is not semantic — it determines which treatments are available (onabotulinumtoxinA requires chronic migraine), which ICD-10 codes apply (G43.7xx for chronic), what quantity of documentation is expected, and which denial pathways will be used against you.
Track frequency before you need it. Payers approving preventive therapy want documented headache frequency — not a clinician's estimate, but actual recorded data. A patient who presents saying "I get migraines all the time" needs a specific frequency in the chart before the PA will hold up. If you don't have a headache diary or tracking tool in place, document frequency at every visit by asking: "How many headache days did you have in the past month?" and recording the number.
Progression from episodic to chronic is common and preventable. Approximately 2.5% of episodic migraine patients progress to chronic migraine each year. Risk factors for progression include high baseline attack frequency (more than 4 days per month), medication overuse, obesity, sleep disorders, and depression. Early preventive intervention in high-frequency episodic patients is the primary strategy for preventing progression.
Chronification is biological, not behavioral. Repeated migraine attacks produce measurable changes in brain structure and pain processing networks — gray matter volume changes, progressive central sensitization, and altered trigeminal function. A patient progressing from episodic to chronic migraine hasn't failed to manage their condition; their disease has progressed. This reframe affects PA documentation: "disease progression from episodic to chronic migraine despite treatment" is substantially stronger than "worsening headaches" or "increasing frequency." Early preventive intervention in high-frequency episodic patients (8–14 days/month) is not just symptom management — it is disease modification aimed at preventing biological chronification. (See Card 18 for pathophysiology context.)
Chronic by history counts for Botox continuation. A patient whose headache frequency has dropped below 15 days per month on Botox still qualifies for continued treatment — document "chronic migraine by history" and note that discontinuation would be expected to cause regression to baseline frequency. This applies to CGRP mAbs as well: a patient whose frequency improved from 18 to 10 days/month on galcanezumab does not lose eligibility because the medication is working.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: ICHD-3 Section 1.3 (Chronic Migraine) — ichd-3.org | AHS 2024 Position Statement — Charles AC et al., Headache 2024;64(4):333-341. doi:10.1111/head.14692 | Lipton RB et al., Neurology 2015;84(17):1759-1765 (progression risk factors) | Goadsby PJ et al., Physiological Reviews 2017;97(2):553-622.